Format

Send to

Choose Destination
Cell Cycle. 2019 Aug;18(15):1798-1811. doi: 10.1080/15384101.2019.1634956. Epub 2019 Jul 1.

Identification and validation of microRNAs that synergize with miR-34a - a basis for combinatorial microRNA therapeutics.

Author information

1
a Department of Biological Sciences , Purdue University , West Lafayette , IN , USA.
2
b Stem Cell Program, Boston Children's Hospital , Harvard Medical School , Boston , MA , USA.
3
c Purdue Center for Cancer Research , Purdue University , West Lafayette , IN , USA.

Abstract

Efforts to search for better treatment options for cancer have been a priority, and due to these efforts, new alternative therapies have emerged. For instance, clinically relevant tumor-suppressive microRNAs that target key oncogenic drivers have been identified as potential anti-cancer therapeutics. MicroRNAs are small non-coding RNAs that negatively regulate gene expression at the posttranscriptional level. Aberrant microRNA expression, through misexpression of microRNA target genes, can have profound cellular effects leading to a variety of diseases, including cancer. While altered microRNA expression contributes to a cancerous state, restoration of microRNA expression has therapeutic benefits. For example, ectopic expression of microRNA-34a (miR-34a), a tumor suppressor gene that is a direct transcriptional target of p53 and thus is reduced in p53 mutant tumors, has clear effects on cell proliferation and survival in murine models of cancer. MicroRNA replacement therapies have recently been tested in combination with other agents, including other microRNAs, to simultaneously target multiple pathways to improve the therapeutic response. Thus, we reasoned that other microRNA combinations could collaborate to further improve treatment. To test this hypothesis miR-34a was used in an unbiased cell-based approach to identify combinatorial microRNA pairs with enhanced efficacy over miR-34a alone. This approach identified a subset of microRNAs that was able to enhance the miR-34a antiproliferative activity. These microRNA combinatorial therapeutics could offer superior tumor-suppressive abilities to suppress oncogenic properties compared to a monotherapeutic approach. Collectively these studies aim to address an unmet need of identifying, characterizing, and therapeutically targeting microRNAs for the treatment of cancer.

KEYWORDS:

Mirna-34; combinatorial therapeutics; miR-34; miR-34a; miRNA therapeutics; synergism

PMID:
31258013
PMCID:
PMC6649554
[Available on 2020-07-01]
DOI:
10.1080/15384101.2019.1634956

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center